Hyundai Pharm Launches "Candevaro Tab," a Combination of Candesartan and S-Amlodipine
Meets Both Convenience and Safety Needs for Hypertension Patients
On October 1, Hyundai Pharm announced the launch of "Candevaro Tab," a combination drug containing candesartan cilexetil and S-amlodipine besylate, both of which are used to treat hypertension.
The main ingredient in Candevaro Tab, candesartan, is an ARB-class drug known for its excellent blood pressure-lowering effects, while S-amlodipine is a CCB-class drug. By isolating only the S-isomer, which has blood pressure-lowering effects, from the mixture of S-amlodipine and R-amlodipine (originally mixed in a 1:1 ratio), the risk of side effects such as edema has been reduced compared to conventional amlodipine. The combination of these two ingredients enables more stable and effective blood pressure management.
The newly launched Candevaro Tab by Hyundai Pharm is available in three dosage strengths: 8/2.5mg, 16/2.5mg, and 16/5mg. It can be prescribed to patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy. By integrating both ingredients into a single formulation, it is expected to significantly improve medication convenience for patients who previously had to take each drug separately.
With the release of Candevaro Tab, Hyundai Pharm has established a comprehensive portfolio of antihypertensive medications, including the leading beta-blocker "Hyundai Tenolmin Tab," the CCB formulation "Varosc Tab," and the ARB-CCB combination "H-Forzi Tab." The company aims to further strengthen its competitiveness in the antihypertensive market through this expanded lineup.
Hot Picks Today
Up to 600 Million Won for Semiconductors, 160 Million Won Bonus for Loss-Making Non-Memory… Samsung Electronics Labor and Management Reach Tentative Deal on Unprecedented Performance Compensation (Comprehensive)
- "Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- [Current State of K-Finance for Foreign Nationals]①From Niche to Core... Banks Go All-In on First-Mover Competition
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
A Hyundai Pharm representative stated, "Candevaro Tab is a product that meets both the convenience and safety needs of hypertension patients. In particular, we expect it to help reduce the burden of side effects for patients who have been taking conventional amlodipine formulations."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
